RefleXion, Telix partner on high-risk cancer treatments

AuntMinnie.com staff writers
Jul 7, 2020
2020 03 12 17 01 2761 Reflexion Astro 2019 400

Radiation therapy equipment developer RefleXion Medical and radiopharmaceutical company Telix Pharmaceuticals are investigating the clinical utility of combining their technologies for improving treatments for high-risk prostate and aggressive kidney cancers.

Under their strategic collaboration agreement, the firms will assess the potential of several new Telix PET tracers, including gallium-68 prostate-specific membrane antigen-11 for prostate cancer and Zr-89-girentuximab for kidney cancer, for guiding RefleXion's biology-guided radiotherapy technology.

Latest in Molecular Imaging
Modern hospital building complex with contemporary architecture, glass facades, and landscaped grounds under blue sky
UW-Madison breaks ground on $62M cyclotron facility
November 2, 2026
Professional headshot of an Asian man in white shirt and dark tie, smiling at camera against gray background
Jeremy Calais discusses his move to Paris, European research
November 2, 2026
See how one team is getting more from SPECT/CT
Sponsored
See how one team is getting more from SPECT/CT
November 2, 2026
Scientific illustration showing chemical formulas, molecular structures, and atomic models on purple gradient background
Eckert & Ziegler gets GMP manufacturing authorization for Ac-225
October 28, 2026
Related Stories
2020 03 12 17 01 2761 Reflexion Astro 2019 400
Radiation Oncology/Therapy
RefleXion's guided lung radiotherapy designated 'breakthrough'
2019 11 11 22 17 5854 Arrows Join Partner 400
Nuclear Medicine
Telix works with Merck on cancer therapies
2021 01 26 19 34 6212 Businessman Plan Graph 400
Molecular Imaging
Telix Japan names COO
See how one team is getting more from SPECT/CT
Sponsor Content
See how one team is getting more from SPECT/CT
More in Molecular Imaging
UW-Madison breaks ground on $62M cyclotron facility
By AuntMinnie.com staff writers
The 13,000-square-foot facility, inside the existing Wisconsin Institutes for Medical Research complex, will house two new cyclotrons.
November 2, 2026
Modern hospital building complex with contemporary architecture, glass facades, and landscaped grounds under blue sky
Jeremy Calais discusses his move to Paris, European research
By Will Morton
The move was driven primarily by family (it is a return home for him and his wife) but it closes a chapter that reshaped nuclear medicine in the U.S.
November 2, 2026
Professional headshot of an Asian man in white shirt and dark tie, smiling at camera against gray background
Fluciclovine PET detects disease in half of PSMA-negative patients
By Will Morton
The findings support a complementary role for F-18 fluciclovine PET in carefully selected patients.
October 29, 2026
PET-CT scan composite showing axial cross-sections of pelvis with radioactive tracer uptake and anatomical structures
Eckert & Ziegler gets GMP manufacturing authorization for Ac-225
By AuntMinnieEurope.com staff writers
The firm is also planning Ac-225 production at its joint venture facility in China and further expansion in the U.S. and Germany.
October 28, 2026
Scientific illustration showing chemical formulas, molecular structures, and atomic models on purple gradient background
SIIM-CAIMI: 20% of advanced imaging prior auth denials get overturned
By Amerigo Allegretto
Advanced imaging prior authorization denials are overturned at a rate of five times that of all Medicare Advantage services.
October 27, 2026
PET/CT scan showing axial, sagittal, and coronal views with metabolic activity visualization in yellow and orange
AdvanCell reports data on Pb-212 PSMA therapy
By AuntMinnie.com staff writers
Eighty percent of patients had a prostate-specific antigen (PSA) decline of at least 50%, according to the company.
October 26, 2026
Medical illustration of prostate gland surrounded by red cancer cells on blue background
EANM: Is ‘research fragmentation’ holding back nuclear medicine?
By Will Morton
Well-designed studies require collaboration among nuclear medicine, medical oncology, urology, radiation oncology, and clinical trial support.
October 21, 2026
Research presentation on nuclear medicine fragmentation showing 25 studies with PET imaging criteria analysis and expert interview
Telix posts revenue growth in Q3
By AuntMinnie.com staff writers
For the period (end-September 30), Telix had group revenues of $245 million, up from $206 million in the same period last year.
October 21, 2026
Business analyst examining financial data charts and percentages through magnifying glass on laptop screen
GEHC begins global clinical evaluation of StarGuide GX SPECT/CT
By AuntMinnie.com staff writers
Participating sites include health centers in the U.S., Europe, and Asia.
October 20, 2026
GE HealthCare CT scanner with gray housing, purple accent ring, and sliding patient table
FAPI-PET detects more HCC lesions than FDG-PET
By Will Morton
Relative to F-18 FDG, F-18 FAPI-PET/CT produced staging changes in 19 of 32 patients undergoing initial staging, including six true upstagings.
October 20, 2026
Comparative PET/CT scan images showing [18F]FAPI and [18F]FDG imaging with MIP projections, fusion views, and CT cross-sections for medical diagnosis
EANM: Thomas Hope on what’s next in FAP-targeted theranostics
By Will Morton
The innovations and work being done to optimize FAP agents will likely "spill over" to other targets.
October 19, 2026
Clinical research presentation slide showing FAP RLT experience data table with patient outcomes across multiple institutions and speaker photo
Nuclidium, NorthStar sign Cu-67 supply and manufacturing deal
By AuntMinnie.com staff writers
Cu-67 is the therapeutic half of Nuclidium’s theranostic platform, which pairs it with copper-61 (Cu-61) for diagnostic imaging.
October 19, 2026
Hand holding glowing atom symbol with blue and gold light effects against blurred tech background
Page 1 of 637
Next Page